Ace Alzheimer Center Barcelona; new member of NANOMED Spain

The Coordinating Committee of NANOMED Spain, an organization of reference in Spain in nanomedicine studies, has accepted the membership application of Ace Alzheimer Center Barcelona, which becomes part of the platform as a research center.

Dr. Amanda Cano, researcher at Ace Alzheimer Center Barcelona, highlights the great added value of being part of Nanomed. Through this new affiliation "we will achieve greater visibility, we will be part of collaborative projects in nanomedicine at a national and international level, we will expand our contact network in this field and we will be updated on the latest advances and calls for grants".

Ace Alzheimer Center Barcelona and nanomedicine

Ace's experience in nanomedicine through different studies on the proteomics of exosomes from Alzheimer's patients places the entity at the epicenter of research in this discipline in Spain.

To date, Ace has participated in the European project EXIT (Exosomes Isolation Tool with nanofluidic concentration Device) which applies nanotechnology to isolate exosomes and investigate metabolic, proteomic, immunological and transcriptional changes in Alzheimer's disease. This project brings the advances in nanotechnology to the diagnosis of Alzheimer's and translates into an etiological, preventive and therapeutic application.

The EXIT study has led to a new project coordinated by Ace and led by Dr. Cano: "Biomarkers in plasmatic exosomes for the early diagnosis of prodromal Alzheimer's disease", which aims to investigate the proteomics of plasmatic exosomes from Alzheimer's patients as a diagnostic tool and a primary screening method.

Nanotechnology in healthcare

Nanomedicine, as the application of nanotechnology to the development of new diagnostic and therapy systems, as well as to the improvement of existing ones, has been identified as a priority in the strategic agendas of both OECD countries and emerging countries. Its implementation is focused on improving the quality of patient service, allowing progress towards a more personalized healthcare technology, with an affordable cost level, offering competitive products with high added value.

NANOMED was born in 2005 with the aim of bringing together the main Spanish academic groups, hospitals, administrations, companies and research centers to promote and facilitate research and innovation in nanomedicine and its application in the development of new therapies and innovative diagnostics.

You might also like

BLOG | Biomarkers: What are they?

Adela Orellana explains what biomarkers are and why research is key to the early detection of dementias.